Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Part of paid clinical trials in Farmington, Connecticut.

Sponsor
UConn Health
Study ID
NCT00408070
Phase
PHASE2
Status
Terminated

Conditions

  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Peritoneal Cancer
  • Stage 3 Cancer
  • Stage 4 Cancer

Eligibility Criteria

Sex
FEMALE
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    cycle 2 (6 cycles re-evaluated and follow up)
  • Carboplatin — DRUG
    cycle #1 and continuous through entire regimen; treated every 3 weeks
  • Paclitaxel — DRUG
    cycle #1 and continuous through entire regimen; treated every 3 weeks

Study Details

The primary objective is to determine whether the addition of bevacizumab to a regimen of carboplatin plus paclitaxel significantly improves Progression Free Survival (PFS) for patient with Stage III suboptimally cytoreduced or Stage IV ovarian, primary peritoneal or fallopian tube carcinomas.

Key Dates

First listed
Dec 6, 2006
Start date
Oct 31, 2006
Status verified
Feb 2018
Primary completion
Aug 31, 2009
Completion
Oct 31, 2009

Study Design

Enrollment
5 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: I
    This is a single Arm study. Two of the study drugs used are non-experimental. One of the study drugs is experimental.

Primary Outcome Measure

Progression Free Survival Rate at 9 Months [ Time Frame: 9 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Connecticut Health CenterFarmingtonConnecticut06030-

Find similar trials in Farmington, CT

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
University of Connecticut Health Center· Farmington, CT

Related Studies